O2881
盐酸奥昔布宁
≥98% (TLC), Muscarinic acetylcholine receptor antagonist, powder
别名:
α-苯基环己烷乙醇酸 4-(二乙基氨基)-2-丁炔酯 盐酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H31NO3 · HCl
化学文摘社编号:
分子量:
393.95
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
216-139-7
MDL number:
产品名称
盐酸奥昔布宁, ≥98% (TLC), powder
Quality Level
InChI key
SWIJYDAEGSIQPZ-UHFFFAOYSA-N
InChI
1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
SMILES string
Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2
assay
≥98% (TLC)
form
powder
color
white
solubility
H2O: 50 mg/mL
originator
Johnson & Johnson
Gene Information
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
毒蕈碱型乙酰胆碱受体拮抗剂。
毒蕈碱型乙酰胆碱受体拮抗剂；可能通过下调生长促进基因，抑制膀胱平滑肌细胞的增殖。
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
K-S Lee et al.
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.
Adding to the evidence base: application drying time for oxybutynin chloride topical gel.
Cynthia M Sublett
Urologic nursing, 32(5), 270-271 (2013-03-12)
Lorne E Aaron et al.
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for
Naoki Aizawa et al.
European urology, 62(6), 1165-1173 (2012-09-18)
Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats
V Schuler et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 19(10), 947-951 (2012-07-25)
A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts in medicine. We have therefore investigated the inhibitory
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持